Richard Book
Family Medicine · Lajunta, CONPI 1164579199
Payments from drug & device makers
Across 175 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$485
- AbbVie$413
- Merck$361
- Johnson & Johnson$140
- Neurocrine Biosciences, Inc.$140
- Amgen$131
- plus $691 from 16 others
What the payments were for
- Food & beverage$2,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $485 |
| AbbVie(2 entities) | 29 | $413 |
| Merck | 27 | $361 |
| Johnson & Johnson | 10 | $140 |
| Neurocrine Biosciences, Inc. | 9 | $140 |
| Amgen | 8 | $131 |
| Pfizer | 8 | $109 |
| AstraZeneca | 8 | $105 |
| Lilly USA, LLC | 6 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Novartis | 4 | $61 |
| Eisai Inc. | 4 | $56 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Organon | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Gilead | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$2,362 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $102,985 |
| MounjaroTirzepatide | 62 | $68,378 |
| JanuviaSitagliptin Phosphate | 37 | $40,212 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $37,852 |
| JardianceEmpagliflozin | 34 | $32,269 |
| FarxigaDapagliflozin Propanediol | 35 | $22,954 |
| TrulicityDulaglutide | 24 | $22,146 |
| RybelsusSemaglutide | 13 | $21,093 |
| BelsomraSuvorexant | 23 | $19,345 |
| MyrbetriqMirabegron | 20 | $18,861 |
| OzempicSemaglutide | 12 | $13,170 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,265 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $7,252 |
| Vilazodone Hcl | 24 | $4,106 |
| Atorvastatin Calcium | 386 | $3,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $109 | $102,985106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $90,52486 claims |
| MerckJanuvia, Belsomra | $361 | $59,55760 claims |
| Novo NordiskRybelsus, Ozempic | $485 | $34,26225 claims |
| AstraZenecaFarxiga, Symbicort | $105 | $30,20657 claims |
| AbbVieSynthroid | $413 | $78712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Lajunta
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
- Astrid LampeyFraser$568K
- Kari UusinarkausWoodland Park$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.